Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer

G. Cserni, G. Boross, R. Maráz, M. H K Leidenius, T. J. Meretoja, P. S. Heikkila, P. Regitnig, G. Luschin-Ebengreuth, J. Zgajnar, A. Perhavec, B. Gazic, G. Lazar, T. Takács, A. Vörös, R. A. Audisio

Research output: Article

22 Citations (Scopus)

Abstract

Sentinel lymph node (SN) biopsy offers the possibility of selective axillary treatment for breast cancer patients, but there are only limited means for the selective treatment of SN-positive patients. Eight predictive models assessing the risk of non-SN involvement in patients with SN metastasis were tested in a multi-institutional setting. Data of 200 consecutive patients with metastatic SNs and axillary lymph node dissection from each of the 5 participating centres were entered into the selected non-SN metastasis predictive tools. There were significant differences between centres in the distribution of most parameters used in the predictive models, including tumour size, type, grade, oestrogen receptor positivity, rate of lymphovascular invasion, proportion of micrometastatic cases and the presence of extracapsular extension of SN metastasis. There were also significant differences in the proportion of cases classified as having low risk of non-SN metastasis. Despite these differences, there were practically no such differences in the sensitivities, specificities and false reassurance rates of the predictive tools. Each predictive tool used in clinical practice for patient and physician decision on further axillary treatment of SN-positive patients may require individual institutional validation; such validation may reveal different predictive tools to be the best in different institutions.

Original languageEnglish
Pages (from-to)59-65
Number of pages7
JournalSurgical Oncology
Volume21
Issue number2
DOIs
Publication statusPublished - jún. 2012

Fingerprint

Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis
Sentinel Lymph Node Biopsy
Lymph Node Excision
Estrogen Receptors
Therapeutics
Physicians
Sensitivity and Specificity
Sentinel Lymph Node
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Cserni, G., Boross, G., Maráz, R., Leidenius, M. H. K., Meretoja, T. J., Heikkila, P. S., ... Audisio, R. A. (2012). Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer. Surgical Oncology, 21(2), 59-65. https://doi.org/10.1016/j.suronc.2011.12.001

Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer. / Cserni, G.; Boross, G.; Maráz, R.; Leidenius, M. H K; Meretoja, T. J.; Heikkila, P. S.; Regitnig, P.; Luschin-Ebengreuth, G.; Zgajnar, J.; Perhavec, A.; Gazic, B.; Lazar, G.; Takács, T.; Vörös, A.; Audisio, R. A.

In: Surgical Oncology, Vol. 21, No. 2, 06.2012, p. 59-65.

Research output: Article

Cserni, G, Boross, G, Maráz, R, Leidenius, MHK, Meretoja, TJ, Heikkila, PS, Regitnig, P, Luschin-Ebengreuth, G, Zgajnar, J, Perhavec, A, Gazic, B, Lazar, G, Takács, T, Vörös, A & Audisio, RA 2012, 'Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer', Surgical Oncology, vol. 21, no. 2, pp. 59-65. https://doi.org/10.1016/j.suronc.2011.12.001
Cserni, G. ; Boross, G. ; Maráz, R. ; Leidenius, M. H K ; Meretoja, T. J. ; Heikkila, P. S. ; Regitnig, P. ; Luschin-Ebengreuth, G. ; Zgajnar, J. ; Perhavec, A. ; Gazic, B. ; Lazar, G. ; Takács, T. ; Vörös, A. ; Audisio, R. A. / Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer. In: Surgical Oncology. 2012 ; Vol. 21, No. 2. pp. 59-65.
@article{7428c228fd8b4a52beba19477de04d5f,
title = "Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer",
abstract = "Sentinel lymph node (SN) biopsy offers the possibility of selective axillary treatment for breast cancer patients, but there are only limited means for the selective treatment of SN-positive patients. Eight predictive models assessing the risk of non-SN involvement in patients with SN metastasis were tested in a multi-institutional setting. Data of 200 consecutive patients with metastatic SNs and axillary lymph node dissection from each of the 5 participating centres were entered into the selected non-SN metastasis predictive tools. There were significant differences between centres in the distribution of most parameters used in the predictive models, including tumour size, type, grade, oestrogen receptor positivity, rate of lymphovascular invasion, proportion of micrometastatic cases and the presence of extracapsular extension of SN metastasis. There were also significant differences in the proportion of cases classified as having low risk of non-SN metastasis. Despite these differences, there were practically no such differences in the sensitivities, specificities and false reassurance rates of the predictive tools. Each predictive tool used in clinical practice for patient and physician decision on further axillary treatment of SN-positive patients may require individual institutional validation; such validation may reveal different predictive tools to be the best in different institutions.",
keywords = "Axillary lymph node dissection, Breast cancer, Non-sentinel lymph nodes, Predictive model, Sentinel lymph node, Validation",
author = "G. Cserni and G. Boross and R. Mar{\'a}z and Leidenius, {M. H K} and Meretoja, {T. J.} and Heikkila, {P. S.} and P. Regitnig and G. Luschin-Ebengreuth and J. Zgajnar and A. Perhavec and B. Gazic and G. Lazar and T. Tak{\'a}cs and A. V{\"o}r{\"o}s and Audisio, {R. A.}",
year = "2012",
month = "6",
doi = "10.1016/j.suronc.2011.12.001",
language = "English",
volume = "21",
pages = "59--65",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Multicentre validation of different predictive tools of non-sentinel lymph node involvement in breast cancer

AU - Cserni, G.

AU - Boross, G.

AU - Maráz, R.

AU - Leidenius, M. H K

AU - Meretoja, T. J.

AU - Heikkila, P. S.

AU - Regitnig, P.

AU - Luschin-Ebengreuth, G.

AU - Zgajnar, J.

AU - Perhavec, A.

AU - Gazic, B.

AU - Lazar, G.

AU - Takács, T.

AU - Vörös, A.

AU - Audisio, R. A.

PY - 2012/6

Y1 - 2012/6

N2 - Sentinel lymph node (SN) biopsy offers the possibility of selective axillary treatment for breast cancer patients, but there are only limited means for the selective treatment of SN-positive patients. Eight predictive models assessing the risk of non-SN involvement in patients with SN metastasis were tested in a multi-institutional setting. Data of 200 consecutive patients with metastatic SNs and axillary lymph node dissection from each of the 5 participating centres were entered into the selected non-SN metastasis predictive tools. There were significant differences between centres in the distribution of most parameters used in the predictive models, including tumour size, type, grade, oestrogen receptor positivity, rate of lymphovascular invasion, proportion of micrometastatic cases and the presence of extracapsular extension of SN metastasis. There were also significant differences in the proportion of cases classified as having low risk of non-SN metastasis. Despite these differences, there were practically no such differences in the sensitivities, specificities and false reassurance rates of the predictive tools. Each predictive tool used in clinical practice for patient and physician decision on further axillary treatment of SN-positive patients may require individual institutional validation; such validation may reveal different predictive tools to be the best in different institutions.

AB - Sentinel lymph node (SN) biopsy offers the possibility of selective axillary treatment for breast cancer patients, but there are only limited means for the selective treatment of SN-positive patients. Eight predictive models assessing the risk of non-SN involvement in patients with SN metastasis were tested in a multi-institutional setting. Data of 200 consecutive patients with metastatic SNs and axillary lymph node dissection from each of the 5 participating centres were entered into the selected non-SN metastasis predictive tools. There were significant differences between centres in the distribution of most parameters used in the predictive models, including tumour size, type, grade, oestrogen receptor positivity, rate of lymphovascular invasion, proportion of micrometastatic cases and the presence of extracapsular extension of SN metastasis. There were also significant differences in the proportion of cases classified as having low risk of non-SN metastasis. Despite these differences, there were practically no such differences in the sensitivities, specificities and false reassurance rates of the predictive tools. Each predictive tool used in clinical practice for patient and physician decision on further axillary treatment of SN-positive patients may require individual institutional validation; such validation may reveal different predictive tools to be the best in different institutions.

KW - Axillary lymph node dissection

KW - Breast cancer

KW - Non-sentinel lymph nodes

KW - Predictive model

KW - Sentinel lymph node

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=84860321861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860321861&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2011.12.001

DO - 10.1016/j.suronc.2011.12.001

M3 - Article

C2 - 22197294

AN - SCOPUS:84860321861

VL - 21

SP - 59

EP - 65

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 2

ER -